

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

K7M2-WT

RRID:CVCL_V455

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2836, RRID:CVCL_V455

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_V455

Proper Citation: ATCC Cat# CRL-2836, RRID:CVCL_V455

Description: Cell line K7M2-WT is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse osteosarcoma

Defining Citation: [PMID:11315100](#), [PMID:17671136](#), [PMID:26320182](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: K7M2-WT

Synonyms: K7M2 wt, K7M2

Cross References: BTO:BTO_0006407, ATCC:CRL-2836, CCRID:1101MOU-PUMC000820, CCRID:3101MOUTCM38, CLS:305188, Wikidata:Q54899432

ID: CVCL_V455

Vendor: ATCC

Catalog Number: CRL-2836

Hierarchy: cvcl_w624

Record Creation Time: 20220427T220656+0000

Record Last Update: 20260829T234359+0000

Ratings and Alerts

No rating or validation information has been found for K7M2-WT.

No alerts have been found for K7M2-WT.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lin S, et al. (2026) Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy. *Acta biomaterialia*, 214, 527.

Malhotra SV, et al. (2026) YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression. *Molecular cancer therapeutics*.

Chen J, et al. (2026) Photodynamic Effect of Bioactive Titanium Metal Initiated by X-Ray and Its Potential Application for Bone Tumor Treatment. *International journal of cancer*.

Yu J, et al. (2026) MnOx-armored magnesium implants for anti-osteosarcoma and biofilm eradication by charge-transfer interference. *Materials today. Bio*, 37, 102817.

Dai C, et al. (2025) Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. *Journal of translational medicine*, 23(1), 900.

Li H, et al. (2025) In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in Monocytes. *Cancer immunology research*, 13(6), 939.

Charalambous A, et al. (2024) Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas. *Molecular cancer therapeutics*, 23(11), 1555.

Deng C, et al. (2024) Extracellular-vesicle-packaged S100A11 from osteosarcoma cells mediates lung premetastatic niche formation by recruiting gMDSCs. *Cell reports*, 43(2), 113751.

Nakazawa K, et al. (2023) Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. *Cancer research communications*, 3(10), 2030.

Zhang W, et al. (2023) Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria. *Cell reports*, 42(9), 113147.

Martinez-Velez N, et al. (2022) Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. *Molecular cancer therapeutics*, 21(3), 471.

Hennesy M, et al. (2021) Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. *International journal of cancer*, 148(8), 1928.

Wedekind MF, et al. (2021) Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. *iScience*, 24(7), 102759.

Hoshino A, et al. (2020) Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. *Cell*, 182(4), 1044.

McGuire JJ, et al. (2020) Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma. *International journal of cancer*, 147(10), 2811.

Fourman MS, et al. (2018) Quantitative Primary Tumor Indocyanine Green Measurements Predict Osteosarcoma Metastatic Lung Burden in a Mouse Model. *Clinical orthopaedics and related research*, 476(3), 479.

Crasto JA, et al. (2018) Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetent Balb/c or-thotopic mouse model. *Oncotarget*, 9(53), 30163.